NCI-2023-03817

Phase 1b/2a safety and tolerability study of bemcentinib with pembrolizumab/carboplatin/pemetrexed in subjects with untreated advanced or metastatic non-squamous non-small cell lung cancer (NSCLC) without/with a STK11 mutation

This Phase 1b/2a study assesses the safety and tolerability of a new drug called bemcentinib alongside pembrolizumab, carboplatin, and pemetrexed in treating non-squamous non-small cell lung cancer (NSCLC). Bemcentinib targets a protein involved in cancer growth, while pembrolizumab boosts the immune system, and carboplatin and pemetrexed are chemotherapy drugs. The goal is to assess the safety and effectiveness of this combination therapy in patients with advanced or spreading NSCLC,

 non-small cell lung cancer (NSCLC): A type of lung cancer with non small cells that grow too much and can spread to other parts of the body

For more information about the trial, click the link below:

https://clinicaltrials.gov/ct2/show/NCT05469178

Clinical Trial Site: Sinai

To see all available clinical trials click here.